Ralliant (NYSE:RAL) Releases Q3 2026 Earnings Guidance

Ralliant (NYSE:RAL) issued an update on its third quarter 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.720-0.780 for the period, compared to the consensus EPS estimate of 0.680. The company issued revenue guidance of $570.0 million-$590.0 million, compared to the consensus revenue estimate of $556.4 million. Ralliant also updated its FY 2026 guidance to 2.760-2.900 EPS.

Ralliant Trading Down 0.0%

Shares of Ralliant stock traded down $0.01 during mid-day trading on Thursday, hitting $66.96. 4,483,291 shares of the stock were exchanged, compared to its average volume of 1,715,994. Ralliant has a twelve month low of $37.27 and a twelve month high of $75.41. The stock has a market capitalization of $7.49 billion and a price-to-earnings ratio of -6.12. The company has a 50-day simple moving average of $66.98 and a 200 day simple moving average of $54.16. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. The business had revenue of $567.80 million during the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Research analysts forecast that Ralliant will post 2.64 EPS for the current year.

Ralliant Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s payout ratio is presently -1.83%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Barclays boosted their price target on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Royal Bank Of Canada raised their price objective on Ralliant from $64.00 to $71.00 and gave the stock a “sector perform” rating in a report on Thursday, July 16th. Oppenheimer lifted their price objective on Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. Vertical Research lowered Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price for the company. in a research note on Wednesday, May 27th. Finally, Morgan Stanley increased their target price on Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $73.00.

Key Ralliant News

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Adjusted earnings and revenue beat expectations. Ralliant reported second-quarter adjusted EPS of $0.68, above the $0.63 consensus and up from $0.67 a year earlier. Revenue reached approximately $568 million, a 13% year-over-year increase and above analyst expectations. Ralliant Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised its 2026 guidance. Full-year adjusted EPS is now expected at $2.76-$2.90, above the $2.65 consensus, while revenue is projected at roughly $2.25-$2.30 billion, above prior market expectations. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Near-term expectations also improved. Third-quarter guidance calls for adjusted EPS of $0.72-$0.78 and revenue of $570 million-$590 million, both above consensus estimates of $0.68 and $556.4 million, respectively.
• Positive Sentiment: Cost savings could support future margins. Ralliant’s enterprise productivity program is expected to generate $50 million-$60 million in annualized savings by 2028, potentially improving profitability and cash generation. Ralliant Forecasts 2026 Revenue and Productivity Savings
• Neutral Sentiment: Trading was volatile. RAL was briefly halted under a limit-up/limit-down pause, indicating elevated intraday volatility around the earnings release rather than a change in the company’s fundamentals.
• Negative Sentiment: Reported results were less favorable than adjusted figures. GAAP EPS was $0.51 versus adjusted EPS of $0.68, and Ralliant continues to face substantial non-operating or special-item effects. Investors may therefore focus on the quality and sustainability of the adjusted earnings improvement.

Hedge Funds Weigh In On Ralliant

A number of large investors have recently bought and sold shares of the stock. Palisade Asset Management LLC acquired a new position in shares of Ralliant in the 3rd quarter valued at $26,000. BOKF NA purchased a new stake in shares of Ralliant during the 3rd quarter valued at $29,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ralliant during the 3rd quarter worth $30,000. EverSource Wealth Advisors LLC acquired a new stake in shares of Ralliant during the 2nd quarter worth $39,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of Ralliant during the 2nd quarter worth $43,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.